ANI Pharmaceuticals Inc (ANIP) stock
ANIPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 14/3048% below fair value
$69.99−0.90 (-1.27%)
Close on Nov 17, 2026Market cap $1.61BP/E 14.9Yield –
ANI Pharmaceuticals total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
ANI Pharmaceuticals's total debt was $301.48M at Jun 30, 2026. For fiscal 2025 it was $309.11M, down 2.9% from the year before. The highest annual figure on record is $318.28M in fiscal 2024.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $309.11M | -2.9% |
| FY2024 | Dec 31, 2024 | $318.28M | +11.4% |
| FY2023 | Dec 31, 2023 | $285.67M | -0.3% |
| FY2022 | Dec 31, 2022 | $286.52M | -0.3% |
| FY2021 | Dec 31, 2021 | $287.37M | +54.8% |
| FY2020 | Dec 31, 2020 | $185.69M | -0.0% |
| FY2019 | Dec 31, 2019 | $185.75M | +163.3% |
| FY2018 | Dec 31, 2018 | $70.55M | -3.7% |
| FY2017 | Dec 31, 2017 | $73.30M | – |
| FY2016 | Dec 31, 2016 | $0 | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $301.48M | -4.2% |
| Q1 FY2026 | Mar 31, 2026 | $305.29M | -3.5% |
| Q4 FY2025 | Dec 31, 2025 | $309.11M | -2.9% |
| Q3 FY2025 | Sep 30, 2025 | $312.92M | -2.2% |
| Q2 FY2025 | Jun 30, 2025 | $314.70M | +10.3% |
| Q1 FY2025 | Mar 31, 2025 | $316.49M | +10.9% |
| Q4 FY2024 | Dec 31, 2024 | $318.28M | +11.4% |
| Q3 FY2024 | Sep 30, 2024 | $320.07M | +12.0% |
| Q2 FY2024 | Jun 30, 2024 | $285.24M | -0.3% |
| Q1 FY2024 | Mar 31, 2024 | $285.46M | -0.3% |
| Q4 FY2023 | Dec 31, 2023 | $285.67M | -0.3% |
| Q3 FY2023 | Sep 30, 2023 | $285.88M | -0.3% |
| Q2 FY2023 | Jun 30, 2023 | $286.09M | -0.3% |
| Q1 FY2023 | Mar 31, 2023 | $286.31M | -0.3% |
| Q4 FY2022 | Dec 31, 2022 | $286.52M | -0.3% |
| Q3 FY2022 | Sep 30, 2022 | $286.73M | +42.0% |
| Q2 FY2022 | Jun 30, 2022 | $286.95M | +40.2% |
| Q1 FY2022 | Mar 31, 2022 | $287.16M | +56.6% |
| Q4 FY2021 | Dec 31, 2021 | $287.37M | +54.8% |
| Q3 FY2021 | Sep 30, 2021 | $201.99M | +7.5% |
| Q2 FY2021 | Jun 30, 2021 | $204.71M | +7.6% |
| Q1 FY2021 | Mar 31, 2021 | $183.42M | -8.3% |
| Q4 FY2020 | Dec 31, 2020 | $185.69M | -0.0% |
| Q3 FY2020 | Sep 30, 2020 | $187.95M | +172.3% |
| Q2 FY2020 | Jun 30, 2020 | $190.21M | +172.4% |
| Q1 FY2020 | Mar 31, 2020 | $199.97M | +186.7% |
| Q4 FY2019 | Dec 31, 2019 | $185.75M | +163.3% |
| Q3 FY2019 | Sep 30, 2019 | $69.03M | -3.7% |
| Q2 FY2019 | Jun 30, 2019 | $69.84M | -3.6% |
| Q1 FY2019 | Mar 31, 2019 | $69.74M | -3.6% |
| Q4 FY2018 | Dec 31, 2018 | $70.55M | -3.7% |
| Q3 FY2018 | Sep 30, 2018 | $71.65M | – |
| Q2 FY2018 | Jun 30, 2018 | $72.48M | – |
| Q1 FY2018 | Mar 31, 2018 | $72.37M | – |
| Q4 FY2017 | Dec 31, 2017 | $73.30M | – |
| Q4 FY2016 | Dec 31, 2016 | $0 | – |
See a number that looks wrong?